Areen Al-Taie, MD
Interventional Cardiology · Florence, ALNPI 1124414958
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (58.1%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Abbott at 47.0% of the total. 2025 is the largest year on record at $52,314, more than ten times the $42 reported in 2019. Among interventional cardiology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 274 payments — averaging $251.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$32K
- Medtronic$25K
- Boston Scientific$6K
- Edwards Lifesciences$5K
- Merck$274
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$256
- plus $1K from 14 others
What the payments were for
- Grants$40,00058%
- Travel & lodging$22,03332%
- Food & beverage$6,77310%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 103 | $32,342 |
| Medtronic | 50 | $24,523 |
| Boston Scientific | 30 | $5,858 |
| Edwards Lifesciences | 32 | $4,523 |
| Merck | 12 | $274 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $256 |
| Pfizer | 11 | $179 |
| Penumbra, Inc. | 1 | $140 |
| Johnson & Johnson | 2 | $131 |
| Irhythm Technologies, Inc. | 4 | $125 |
| Cardiovascular Systems Inc. | 1 | $119 |
| AstraZeneca | 1 | $110 |
| Novartis | 4 | $62 |
| Impulse Dynamics (USA) Inc. | 1 | $43 |
| Amgen | 2 | $32 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Bayer | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$22,146
- VersaCross Access Solution$2,703
- AVEIR$1,994
- AMPLATZER AMULET$1,889
- ACCENT$1,853
- AMPLATZER TALISMAN$1,617
- WATCHMAN Access System$1,557
- COREVALVE EVOLUT R$1,386
- VersaCross Steerable Access Solution$1,115
- NAVITOR$1,092
- PASCAL$992
- Micra$789
- EVERA MRI XT DR SURESCAN$653
- SAPIEN 3 Ultra RESILIA$596
- Optis Coronary Imaging System$157
- Edwards SAPIEN 3 Transcatheter Heart Valve$144
- Indigo System$140
- QUARTET$128
- Diamondback Coronary$119
- XARELTO$116
How this compares
$68,807 in reported general payments places this provider in the 90th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 341 | $354,427 |
| EntrestoSacubitril/Valsartan | 161 | $175,067 |
| XareltoRivaroxaban | 101 | $105,413 |
| FarxigaDapagliflozin Propanediol | 84 | $79,054 |
| VerquvoVericiguat | 44 | $33,725 |
| BrilintaTicagrelor | 39 | $29,370 |
| Repatha SureclickEvolocumab | 14 | $17,674 |
| Ranolazine ErRanolazine | 86 | $11,368 |
| JardianceEmpagliflozin | 12 | $9,370 |
| Amiodarone Hcl | 100 | $7,083 |
| VascepaIcosapent Ethyl | 13 | $6,634 |
| Icosapent Ethyl | 18 | $5,084 |
| Metoprolol Succinate | 297 | $4,923 |
| Atorvastatin Calcium | 304 | $4,142 |
| Rosuvastatin Calcium | 195 | $3,695 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $179 | $354,427341 claims |
| NovartisEntresto | $62 | $175,067161 claims |
| AstraZenecaFarxiga, Brilinta | $110 | $108,424123 claims |
| Johnson & JohnsonXarelto | $131 | $105,413101 claims |
| MerckVerquvo | $274 | $33,72544 claims |
| Boehringer IngelheimJardiance | $12 | $9,37012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Florence
- Anand MishraFlorence$34K
- Therese LangoFlorence$34K
- Gary RoubinBirmingham$157K
- Michael ButlerHuntsville$109K
- Pochana ReddyHuntsville$100K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
- John GallaMobile$82K
- Abdullah MahmoodBirmingham$61K
- Ali EbrahimiBirmingham$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.